

CORRECTION

Open Access



Correction to: Fluticasone furoate/Vilanterol 92/22 µg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 µg b.i.d.: a 12-month comparison of outcomes in mild-to-moderate asthma

Roberto W. Dal Negro^{1*}, Luca Bonadiman¹ and Paola Turco²

Correction to: *Multidisciplinary Respiratory Medicine* (2018) 13:18 DOI: 10.1186/s40248-018-0131-x

After publication of the Original research article [1] it was brought to our attention that the sentence at pag 6 (between Fig. 3 and Fig. 4)) must be corrected as follows: “The mean duration of inactivity was 2.88 (0.63) at baseline; 1.53 (0.27) after 3; 1.40 (0.27) after 6, and 1.45 days (0.58) after twelve months (Anova: $p = 0.11$) in group A, while the corresponding duration in group B was 3.35 (0.63) at baseline; 0.60 (0.19) after 3; 1.10 (0.21) after 6, and 0.83 days (0.39) after 12 months (Anova; $p < 0.001$), respectively.”

In addition at pag. 7 Fig. 5 entitled “Changes in mean duration of inactivity/p. over 12 months” must be substituted with the new Fig. 5 because there is a mistake regarding **anova p = 0.11** and consequently in the whole image. This Correction shows the revised Fig. 5. The original article has been updated.




Fig. 5 Changes in mean duration of inactivity/p. over 12 months

Author details

¹National Centre for Respiratory Pharmacoeconomics and Pharmacoepidemiology, Verona, Italy. ²Research & Clinical Governance, Verona, Italy.

Received: 28 June 2018 Accepted: 28 June 2018

Published online: 24 July 2018

Reference

1. Negro D, et al. Fluticasone furoate/Vilanterol 92/22 µg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 µg b.i.d.: a 12-month comparison of outcomes in mild to-moderate asthma. *Multidisciplinary Respiratory Medicine*. 2018;13:18.

* Correspondence: robertodalnegro@gmail.com

¹National Centre for Respiratory Pharmacoeconomics and Pharmacoepidemiology, Verona, Italy

Full list of author information is available at the end of the article

